"Developing novel treatments for Dormant Cancers - targeting resistance, metastasis, and relapse."
Felicitex Therapeutics is a drug discovery company at the forefront of one of the most promising areas in oncology –dormant (quiescent) cancer cells. We are developing treatments and diagnostic assays to improve the effectiveness and long-term outcomes of treatments for the deadliest and most therapy resistant cancers: hematopoietic, ovarian, pancreatic, colorectal, and lung.
It is well established that most tumors are heterogeneous. While some of the cancer cells divide rapidly others do not. They are staying in the dormant state using it as a survival niche. This is especially true of solid tumors in which the cells in the outer layers are proliferating, but the inner volume comprises a large proportion of dormant (quiescent) cells, frequently as a result of inadequate nutrient supply and oxygen deprivation (hypoxia). Hypoxic regions have long been known to be resistant to chemotherapy and radiation treatment. Tumor hypoxia, as a target for chemotherapy, is currently an active area of research.
Moreover, when cancer cells are under stress from either chemotherapy, anti-angiogenesis therapy, specific targeted treatment, or radiation, cancer cells often go into dormant state (G0), using quiescent as a niche to hide. After the completion of treatment, these cells can acquire resistance to the current treatment, begin growing and cause cancer recurrence. This process is called pharmacological quiescence.
© 2019 by Felicitex Therapeutics, Inc »« 27 Strathmore Road Natick, MA 01760 1-919-213-0025 (p) Click here to Contact Us!